Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Post by eSnowdenon May 22, 2017 11:24am

176 Views

Post# 26270257

Amazing what our competitor has done...

MPH has apparently switched roles with Cardiome, who has the european rights to Aggrastat. What was once a struggling co. now has a valuation over $50m higher than us. Medicure now has an $80m valuation (USD) where CRME once was, now CRME has a $135m valuation, where MPH once was. I have a feeling Friessen has dropped the ball on this one, the street certainly doesn't like the Apicore transaction given the decline in share price.

Bullboard Posts

A PGM mining stock with value written all over it